Methods for treatment of cancers with EGFR activating mutations
AssigneeBoard of Regents, The University of Texas System
InventorsJohn V. Heymach, Monique Nilsson, Jacqulyne Robichaux
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating cancer in a patient determined to have an EGFR activating mutation by administering a CDK inhibitor and/or SAC component inhibitor.
Claims6
A method of treating non-small cell lung cancer (NSCLC) in a subject comprising administering an effective amount of a cyclin dependent kinase (CDK) inhibitor to the subject, wherein the NSCLC is determined to have one or more EGFR activating mutations selected from the group consisting of an E746-A750 deletion, L747-E749 deletion, A750P, and N771Del Ins FH, is resistant to one or more tyrosine kinase inhibitors (TKIs), and has undergone epithelial to mesenchymal transition (EMT) and wherein the subject is determined to not have a T790M mutation and the CDK inhibitor is a CDK2 inhibitor, CDK5 inhibitor, CDK1 inhibitor, and/or CDK9 inhibitor.
Dependencies are inferred from the claim text.